Gene Editing: Rewriting The Code
This article was originally published in Start Up
Gene editing technologies, which enable knockout or modification of specific genes, could get first use in modifying T cells to fight cancer and HIV, but its long-term potential to control gene expression in vivo has sparked Series A financings of three start-ups in the past 18 months.
You may also be interested in...
Deal-Making, Financing Coalesce Around Promising CAR-T Space In Cancer
A huge IPO for Kite Pharma and two massive venture rounds for Juno Therapeutics have those two newer companies out in front in CAR therapeutics, but bigger, more established firms like Novartis, Pfizer and Celgene are in the game, while other companies, like biotech Bellicum, are looking to get in. Can Kite and Juno stay ahead and stand alone?
Sangamo On A Roll, Clarifies Timelines And Catalysts, Takes On CRISPR
Sangamo used 2013 to progress its pipeline, to raise money and to acquire a company. The momentum carried into the first quarter of 2014 with the Biogen partnership and a jump in share price that suggested that investors finally may have bought into the gene therapy company’s unique story.
Homology Medicines Inc.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.